A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Inclusion Criteria

• Must have metastatic colorectal or pancreatic cancer
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
• Ability to swallow pills or capsules
• Required to undergo mandatory pre and on-treatment biopsies
• Adequate marrow function
• Adequate other organ functions
• Ability to comply with study visits, treatment, procedures, pharmacokinetic (PK) and pharmacodynamic (PD) sample collection, and required study follow-up

Exclusion Criteria

• Histology other than adenocarcinoma (neuroendocrine or acinar cell)
• Suspected, known, or central nervous system (CNS) metastases (Imaging required only if participants are symptomatic)
• Active, known or suspected autoimmune disease
• Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
• Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
• Prior treatment with cysteine-cysteine chemokine receptor 2 (CCR2) and/or cysteine-cysteine chemokine receptor 5 (CCR5) inhibitors, programmed death-1 receptor (PD-1), programmed death-ligand 1 [PD(L)-1] or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies
• History of allergy to study treatments or any of its components of the study arm that participant is enrolling Other protocol-defined inclusion/exclusion criteria apply